NanoGhost is a biotech company that develops a highly selective first-in-class drug delivery platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.
NanoGhost offers a novel, versatile, and highly selective targeted drug delivery platform for the treatment of oncological diseases.
NanoGhosts can be loaded with various drug types, preserve MSCs tropism to cancer cells, and selectively penetrate tumors (including brain tumors while crossing the BBB and pancreatic cancer), leading to a major reduction in tumor size and prolonged survival.
Company Details
- Employees
- 12
- Founded
- -
- Address
- 12 Beni Ga’on St., Netanya,israel,israel
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.nano-ghost.com/
- Keywords
- Nanotechnology, Oncology, Bio-convergence.
- HQ
- Netanya, Israel
Nanoghost Questions
Nanoghost's website is https://www.nano-ghost.com/
Nanoghost's LinkedIn profile is https://il.linkedin.com/company/nanoghost
Nanoghost has
12 employees.
View email and phone details for 12
employees at Nanoghost.
Nanoghost's industry is
Biotechnology Research
Nanoghost's top competitors are
Amai Proteins,
Biomx (Nyse: Phge),
Aidoc,
Brainstorm Cell Therapeutics,
Cytoreason,
Precise Bioscience, Inc,
Precise Bio,
Meatafora,
Evogene,
Protalix Biotherapeutics.
Nanoghost's categories are Biotechnology Research
Nanoghost's founding year is 2019
